On February 24, 2021, 依生生物制药有限公司 announced completion of a Series B financing of more than $130 million. The round was co‑led by Oceanpine Capital (海松资本) and OrbiMed (奥博资本). Following the transaction, the company's institutional investor base included Oceanpine, OrbiMed, 斯道资本, F‑Prime Capital, 3W Capital, 高瓴资本, Adjuvant Capital, 和玉资本, AIHC, 益普资本, Superstring Capital and 海通国际. 易凯资本 served as the company's exclusive financial adviser on the deal. The financing expanded the company's investor roster and represents a significant recapitalization event at the B‑round stage. No additional product, operational or use‑of‑proceeds details for the company were provided in the articles.

Total raised

$130M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2024